Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder TrialMarket Beat·50 minutes agoALT-1.52%
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga_article·2 hours agoALT-1.52%OTLK-13.36%
ALT: Pemvidutide met key efficacy endpoints in AUD, reducing heavy drinking and increasing abstinenceQuartr·3 hours agoALT-1.52%
Altimmune reports positive Phase 2 RECLAIM topline results for pemvidutide in AUDTradingView·3 hours agoALT-1.52%
Biotech and CXO Clinical Momentum: 7 Core Companies Set for Late-2026 BreakoutsGlobal Report·Jul 9 at 05:02 AMBVS+4.46%ALT-1.52%
Altimmune shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $10 price target.benzinga_article·Jun 22 at 12:47 PMALT-1.52%
Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data NearMarket Beat·Jun 10 at 08:05 AMALT-1.52%
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH TrialMarket Beat·Jun 4 at 10:08 PMALT-1.52%
